Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, SPA, for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks